[Form 4] COLGATE PALMOLIVE CO Insider Trading Activity

Rhea-AI Filing Summary

Tsourapas Panagiotis, Colgate-Palmolive Company COO (Eur., APac, Afr Eur, Skin) reported equity awards on 09/11/2025. The filing shows a grant of 4,759 restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant. The report also discloses 32,949 stock options with an exercise price of $84.06; the options vest in equal annual installments over three years beginning on 09/11/2026 and expire on 09/11/2033. Following the transactions, the reporting person directly beneficially owns 11,996 shares and beneficially owns additional shares indirectly: 4,509 via the issuer's 401(k) plan trustee and 60,745 via trust (which includes 10,774 previously reported as direct). The form was signed 09/12/2025.

Insights

Financial Analyst

TL;DR Routine executive compensation grants: RSUs and options increase insider alignment without immediate cash impact.

The filing documents standard incentive awards to a senior executive: a 4,759 RSU grant with three-year annual vesting and 32,949 stock options at a $84.06 strike price exercising over three years beginning one year after grant and expiring in 2033. These awards are compensatory, intended to retain and motivate management; they do not reflect open-market purchases or dispositions. The disclosure also clarifies current beneficial ownership across direct and indirect accounts, useful for calculating insider stake and potential future dilution when options are exercised or RSUs vest.

Corporate Governance Expert

TL;DR Governance disclosure is complete for this Form 4: grant types, vesting schedules, exercise price, and beneficial ownership are stated.

The Form 4 provides the necessary details for compliance: grant dates, award types (restricted stock units and options), vesting schedules, strike price, underlying share counts, and post-transaction holdings including indirect holdings via a 401(k) trustee and trust. The inclusion of previously reported shares within the trust is noted. No departures, accelerations, or unusual transaction codes are reported; this appears to be a routine compensation-related filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tsourapas Panagiotis

(Last) (First) (Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO, Eur., APac, Afr Eur, Skin

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		A(1)		4,759	A	$0.0000	11,996	D
Common Stock								4,509	I	By Issuer's 401(k) Plan Trustee
Common Stock								60,745(2)	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$84.06	09/11/2025		A(3)		32,949		(4)	09/11/2033	Common Stock	32,949	$0.0000	32,949	D

Explanation of Responses:

1. Restricted stock unit award granted under the issuer's incentive compensation plan. The restricted stock unit award vests in equal 1/3 installments on each of the first, second and third anniversary of the date of grant.

2. This amount includes 10,774 shares that were previously reported as directly beneficially owned.

3. Stock option award granted under the issuer's incentive compensation plan.

4. Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the September 11, 2025 grant date.

	/s/ Kristine Hutchinson, Attorney-in-Fact	09/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Tsourapas Panagiotis report on Form 4 for CL?

The filing reports 4,759 restricted stock units and 32,949 stock options granted on 09/11/2025.

When do the RSUs and options vest for the 09/11/2025 grants?

The RSUs vest in equal one-third installments on each of the first, second and third anniversaries of the grant date; the options vest in equal annual installments over three years beginning on 09/11/2026.

What is the exercise price and expiration date of the option grant?

The stock options have an exercise price of $84.06 and expire on 09/11/2033.

How many Colgate-Palmolive shares does the reporting person beneficially own after the transaction?

Following the reported transactions the filing shows 11,996 shares directly beneficially owned and additional indirect holdings of 4,509 (401(k)) and 60,745 (trust).

Does the Form 4 indicate any dispositions or open-market trades?

No. The transactions reported are grants (transaction code A); there are no open-market purchases or sales disclosed in this Form 4.